Technical bottleneck in guide stability and the blind spot of the 3′ extension in prime‑editing constructs Prime editors (PE) represent the pinnacle of next‑generation genome engineering, enabling precise base substitution, insertion, and deletion without double‑strand DNA breaks. However, in disease models and preclinical pipelines, the 3′ extension of the prime‑editing guide RNA (pegRNA) is exposed to intracellular nuclease stress, leading to rapid degradation—a structural bottleneck. Early loss of the guide collapses the reverse‑transcriptase domain’s priming and extension kinetics, creating a critical blind spot that severely limits overall genotype‑correction efficiency.

PE‑PRISM high‑speed pooled‑screening architecture: multidimensional evolutionary screening of 2,858 RNA motifs In the study released this May, the authors developed PE‑PRISM, a unique ultra‑fast pooled‑screening platform designed to physically protect the 3′ terminus of pegRNA and maximize binding stability of the editor complex. They assembled a library of 2,858 RNA structural motifs—including naturally occurring and synthetically engineered pseudoknots, G‑quadruplexes, and reverse‑transcriptase recruitment elements—and performed four iterative screening cycles in human cell lines. This structure‑guided mutagenesis and combinatorial variant‑screening pipeline identified sequence architectures with extreme nuclease resistance, providing a scalable breakthrough for in‑vivo applications.

Evolutionary pseudoknot variants and precise correction of 847 pathogenic ClinVar mutations The high‑throughput evolutionary screen yielded evolved pseudoknot variants such as tevo2.0, eHAV, and eSBRMV1‑A, which generate steric hindrance that dramatically extends the intracellular half‑life of the guide RNA. To demonstrate clinical relevance, the team conducted a mega‑screen correcting 847 pathogenic ClinVar loci. The newly engineered motifs completely abolished the efficiency barrier imposed by the widely used tevopreQ backbone, driving explosive increases in target‑editing rates while maintaining baseline levels of cytotoxicity and off‑target noise, thereby proving superior fidelity.

Establishment of a programmable nucleic‑acid stabilization backbone and reduction of gene‑therapy IND lead time The structural‑genomics and screening dataset delivers a disruptive impact on next‑generation gene‑therapy R&D and synthetic‑biology businesses. With the definition of a “plug‑in 3′ RNA stabilization motif specification,” pegRNA half‑life can be independently tuned, allowing therapeutic thresholds to be reached with minimal editor dosing and without excessive viral‑vector or lipid‑nanoparticle administration. This constitutes a robust hardware‑level safeguard that fundamentally avoids immunogenicity and genotoxicity risks in preclinical stages, and it will serve as a reference standard to accelerate large‑scale disease‑model screening and dramatically shorten regulatory timelines for future genomic‑medicine pipelines.